J
Jean-Charles Soria
Researcher at Université Paris-Saclay
Publications - 152
Citations - 35972
Jean-Charles Soria is an academic researcher from Université Paris-Saclay. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 51, co-authored 120 publications receiving 27221 citations. Previous affiliations of Jean-Charles Soria include University of Paris & AstraZeneca.
Papers
More filters
Journal ArticleDOI
Pembrolizumab for the treatment of non-small cell lung cancer
Edward B. Garon,Naiyer A. Rizvi,Rina Hui,Natasha B. Leighl,Ani Sarkis Balmanoukian,Joseph Paul Eder,Amita Patnaik,Charu Aggarwal,Matthew A. Gubens,Leora Horn,Enric Carcereny,Myung-Ju Ahn,Enriqueta Felip,Jong-Seok Lee,Matthew D. Hellmann,Omid Hamid,Jonathan W. Goldman,Jean-Charles Soria,Marisa Dolled-Filhart,Ruth Z. Rutledge,Jin Zhang,Jared Lunceford,Reshma A. Rangwala,Gregory M. Lubiniecki,Charlotte Roach,Kenneth Emancipator,Leena Gandhi +26 more
TL;DR: Pembrolizumab had an acceptable side-effect profile and showed antitumor activity in patients with advanced non-small-cell lung cancer and PD-L1 expression in at least 50% of tumor cells correlated with improved efficacy of pembrolIZumab.
Journal ArticleDOI
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst,Jean-Charles Soria,Marcin Kowanetz,Gregg Fine,Omid Hamid,Michael S. Gordon,J. A. Sosman,David F. McDermott,John D. Powderly,Scott N. Gettinger,Holbrook E Kohrt,Leora Horn,Donald P. Lawrence,Sandra Rost,Maya Leabman,Yuanyuan Xiao,Ahmad Mokatrin,Hartmut Koeppen,Priti S. Hegde,Ira Mellman,Daniel S. Chen,F. Stephen Hodi +21 more
TL;DR: Evaluated data suggest that MPDL3280A is most effective in patients in which pre-existing immunity is suppressed by PD-L1, and is re-invigorated on antibody treatment, as well as across multiple cancer types.
Journal ArticleDOI
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
Bertrand Routy,Bertrand Routy,Bertrand Routy,Lisa Derosa,Lisa Derosa,Lisa Derosa,Connie P.M. Duong,Connie P.M. Duong,Maryam Tidjani Alou,Maryam Tidjani Alou,Maryam Tidjani Alou,Romain Daillère,Romain Daillère,Romain Daillère,Aurélie Fluckiger,Aurélie Fluckiger,Meriem Messaoudene,Meriem Messaoudene,Conrad Rauber,Conrad Rauber,Conrad Rauber,Maria Paula Roberti,Maria Paula Roberti,Marine Fidelle,Marine Fidelle,Caroline Flament,Caroline Flament,Vichnou Poirier-Colame,Vichnou Poirier-Colame,Paule Opolon,Christophe Klein,Kristina Iribarren,Laura Mondragón,Nicolas Jacquelot,Nicolas Jacquelot,Nicolas Jacquelot,Bo Qu,Bo Qu,Bo Qu,Gladys Ferrere,Gladys Ferrere,Gladys Ferrere,Céline Clémenson,Céline Clémenson,Laura Mezquita,Jordi Remon Masip,C. Naltet,Solenn Brosseau,Coureche Kaderbhai,Corentin Richard,Hira Rizvi,Florence Levenez,Nathalie Galleron,Benoit Quinquis,Nicolas Pons,Bernhard Ryffel,Veronique Minard-Colin,Patrick Gonin,Jean-Charles Soria,Eric Deutsch,Eric Deutsch,Yohann Loriot,Yohann Loriot,François Ghiringhelli,Gérard Zalcman,François Goldwasser,B. Escudier,B. Escudier,Matthew D. Hellmann,Matthew D. Hellmann,Alexander M.M. Eggermont,Alexander M.M. Eggermont,Didier Raoult,Laurence Albiges,Laurence Albiges,Guido Kroemer,Laurence Zitvogel +76 more
TL;DR: It is found that primary resistance to ICIs can be attributed to abnormal gut microbiome composition, and Antibiotics inhibited the clinical benefit of ICIs in patients with advanced cancer.
Journal ArticleDOI
Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
Jean-Charles Soria,Yuichiro Ohe,Johan Vansteenkiste,Thanyanan Reungwetwattana,Busyamas Chewaskulyong,Ki Hyeong Lee,Arunee Dechaphunkul,Fumio Imamura,Naoyuki Nogami,Takayasu Kurata,Isamu Okamoto,Caicun Zhou,Byoung Chul Cho,Ying Cheng,Eun Kyung Cho,Pei Jye Voon,David Planchard,Wu Chou Su,Jhanelle E. Gray,Siow-Ming Lee,Rachel Hodge,Marcelo Marotti,Yuri Rukazenkov,Suresh S. Ramalingam +23 more
TL;DR: Osimertinib showed efficacy superior to that of standard EGFR‐TKIs in the first‐line treatment of EGFR mutation–positive advanced NSCLC, with a similar safety profile and lower rates of serious adverse events.
Journal ArticleDOI
DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.
Ken A. Olaussen,Ariane Dunant,Pierre Fouret,Elisabeth Brambilla,Fabrice Andre,Vincent Haddad,E. Taranchon,Martin Filipits,Robert Pirker,Helmut Popper,R. Stahel,Laure Sabatier,Jean-Pierre Pignon,Thomas Tursz,Thierry Le Chevalier,Jean-Charles Soria +15 more
TL;DR: Patients with completely resected non-small-cell lung cancer and ERCC1-negative tumors appear to benefit from adjuvant cisplatin-based chemotherapy, whereas patients with ER CC1-positive tumors do not.